The polymorphism of progesterone: Stabilization of a 'disappearing' polymorph by co-crystallization

Journal of Pharmaceutical Sciences

Volumn 96, Issue 12, 2007, Pages 3419-3431

  Lancaster, Robert W ^a   Karamertzanis, Panagiotis G ^a   Hulme, Ashley T ^a,b   Tocher, Derek A ^a   Lewis, Thomas C ^a,c   Price, Sarah L ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Pharmorphix Ltd   (United Kingdom)

^c Science and Technology Centre   (United Kingdom)

Author keywords

Co crystals; Computational crystal structure prediction; Computer aided drug design; Concomitant polymorphs; Crystal structure; Crystallization; Disappearing polymorphs; Polymorphism; Progesterone

Indexed keywords

PREGNENOLONE; PROGESTERONE;

ARTICLE; CRYSTAL STRUCTURE; CRYSTALLIZATION; ENANTIOMER;

EID: 38149125492     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20983     Document Type: Article

References (61)

1. Dunitz JD, Bernstein J. 1995. Disappearing Polymorphs. Accounts Chem Res 28:193-200.
2. Chemburkar SR, Bauer J, Deming K, Spiwek H, Patel K, Morris J, Henry R, Spanton S, Dziki W, Porter W, Quick J, Bauer P, Donaubauer J, Narayanan BA, Soldani M, Riley D, McFarland K. 2000. Dealing with the impact of ritonavir polymorphs on the late stages of bulk drug process development. Organic Process Res Dev 4:413-417.
3. Threlfall T. 2000. Crystallisation of polymorphs: Thermodynamic insight into the role of solvent. Organic Process Res Dev 4:384-390.
4. Florence AJ, Johnston A, Price SL, Nowell H, Kennedy AR, Shankland N. 2006. An automated parallel crystallisation search for predicted crystal structures and packing motifs of carbamazepine. J Pharm Sci 95:1918-1930.
5. Price CP, Grzesiak AL, Matzger AJ. 2005. Crystalline polymorph selection and discovery with polymer heteronuclei. J Am Chem Soc 127:5512-5517.
6. Mitchell CA, Yu L, Ward MD. 2001. Selective nucleation and discovery of organic polymorphs through epitaxy with single crystal substrates. J Am Chem Soc 123:10830-10839.
7. Day GM, Trask AV, Motherwell WDS, Jones W. 2006. Investigating the latent polymorphism of maleic acid. Chem Commun 54-56.
8. Vishweshwar P, McMahon JA, Oliveira M, Peterson ML, Zaworotko MJ. 2005. The Predictable Elusive Form II of Aspirin. J Am Chem Soc 127: 16802-16803.
9. Price SL. 2004. The computational prediction of pharmaceutical crystal structures and polymorphism. Adv Drug Deliver Rev 56:301-319.
10. Lancaster RW, Karamertzanis PG, Hulme AT, Tocher DA, Covey DF, Price SL. 2006. Racemic Progesterone: Predicted in silico and produced in the solid state. Chem Commun 4921-4923.
11. Hirvonen E. 1999. Progestins. Maturitas-Journal of the Climacteric & Postmenopause 23:S13-S18.
12. Fieser LFFM. 1959. Steroids. New York: Reinhold.
13. Brandstätter-Kuhnert M, Kofier A. 1959. Zur mikroskopischen Identitätsprüfung und zur Polymorphie der Sexualhormone. Mikrochim Acta 47:847-853.
14. Legendre B, Feutelais Y, Defossemont G. 2003. Importance of heat capacity determination in homogeneous nucleation: application to progesterone. Thermochimica Acta 400:213-219.
15. Campsteyn H, Dupont L, Dideberg O. 1972. Structure Cristalline et Moléculaire de la Progestérone,C21H30 O2. Acta Crystallogr, Sect B 28:3032-3042.
16. Foresti Serantoni E, Krajewski A, Mongiorgi R, Riva de Sanseverino L, Cameroni R. 1975. 4-Pregnen-3,20-Dione (Progesterone, Form 2). Cryst Struct Commun 4:189-192.
17. Allen FH. 2002. The Cambridge Structural Database: a quarter of a million crystal structures and rising. Acta Crystallogr, Sect B 58:380-388.
18. Auchus RJ, Kumar AS, Boswell CA, Gupta MK, Bruce K, Rath NP, Covey DF. 2003. The enantiomer of progesterone (ent-progesterone) is a competitive inhibitor of human cytochromes P450c17 and P450c21. Arch Biochem Biophys 409:134-144.
19. Wang F, Wachter JA, Antosz FJ, Berglund KA. 2000. An investigation of solvent mediated polymorphic transformation of progesterone using in situ Raman spectroscopy. Organic Process Res Dev 4:391-395.
20. Wachter JA. 2004. Personal Communication
21. Finar IL. 1975. Organic Chemistry: Stereochemistry and the Chemistry of Natural Products. 5th edition. London: Longman. p 517-605.
22. Mesley RJ, Johnson CA. 1965. Infrared identification of pharmaceutically important steroids with particular reference to occurrence of polymorphism. J Pharm Pharmacol 17:329-340.
23. Bruker AXS Inc. 2001. SMART., Madison, Wisconsin, USA. Computer Program.
24. Bruker AXS Inc. 2001. SAINT+., Madison, Wisconsin, USA. Computer Program.
25. Sheldrick GM. 1997. SHELXS97., Göttingen, Germany: University of Göttingen. Computer Program.
26. Sheldrick GM1997. SHELXL97., Göttingen, Germany: University of Göttingen. Computer Program.
27. Sheldrick GM2001. SADABS v2.05., Madison, Wisconsin, USA: Bruker AXS Inc. Computer Program.
28. Payne RS, Roberts RJ, Rowe RC, Docherty R. 1999. Examples of successful crystal structure prediction: Polymorphs of primidone and progesterone. Int J Pharm 177:231-245.
29. Allen FH, Baalham CA, Lommerse JPM, Raithby PR. 1998. Carbonyl-carbonyl interactions can be competitive with hydrogen bonds. Acta Crystallogr, Sect B 54:320-329.
30. Karamertzanis PG, Price SL. 2006. Energy Minimization of Crystal Structures Containing Flexible Molecules. J Chem Theory Comput 2: 1184-1199.
31. Price SL, Willock DJ, Leslie M, Day GM. 2001. DMAREL 3.02. http://www.ucl.ac.uk/~ucca17p/dmarelmanual/dmarel.html. Computer Program.
32. Coombes DS, Price SL, Willock DJ, Leslie M. 1996. Role of electrostatic interactions in determining the crystal structures of polar organic molecules. A Distributed Multipole Study. J Phys Chem 100: 7352-7360.
33. Stone AJ, Alderton M. 1985. Distributed multipole analysis - methods and applications. Mol Phys 56: 1047-1064.
34. Stone AJ. 1999. GDMA: A Program for Performing Distributed Multipole Analysis of Wave Functions Calculated Using the Gaussian Program System. United Kingdom: University of Cambridge, Computer Program.
35. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Zakrzewski VG, Montgomery JA Jr, Stratmann RE, Burant JC, Dapprich S, Millam JM, Daniels AD, Kudin KN, Strain MC, Farkas O, Tomasi J, Barone V, Cossi M, Cammi R, Mennucci B, Pomelli C, Adamo C, Clifford S, Ochterski J, Petersson GA, Ayala PY, Cui Q, Morokuma K, Malick DK, Rabuck AD, Raghavachari K, Foresman JB, Cioslowski J, Ortiz JV, Baboul AG, Stefanov BB, Liu G, Liashenko A, Piskorz P, Komaromi I, Gomperts R, Martin RL, Fox DJ, Keith T, Al-Laham MA, Peng CY, Nanayakkara A, Challacombe M, Gill PMW, Johnson B, Chen W, Wong MW, Andres JL, Gonzalez C, Head-Gordon M, Replogle ES, Pople JA. 1998. Gaussian98, Revision A.9. Pittsburgh PA: Gaussian, Inc. Computer Program.
36. Threlfall T. 2000. Personal Communication.
37. CCDC. 2004. Mercury http://www.ccdc.cam.ac.uk/products/csd_system/ mercury/. Computer Program.
38. Duax WL, Griffin JF, Rohrer DC. 1981. Conformation of progesterone side-chain - conflict between X-ray data and force-field calculations. J Am Chem Soc 103:6705-6712.
39. Muramatsu M, Iwahashi M, Takeuchi U. 1979. Thermodynamic relationship between alpha-forms and beta-forms of crystalline progesterone. J Pharm Sci 68:175-177.
40. Brock CP, Schweizer WB, Dunitz JD. 1991. On the validity of wallach rule - on the density and stability of racemic crystals compared with their chiral counterparts. J Am Chem Soc 113: 9811-9820.
41. Rubin-Preminger JM, Bernstein J. 2005. 3-Aminobenzenesulfonic acid: A disappearing polymorph. Cryst Growth Des 5:1343-1349.
42. Coquerel G. 2006. Thermodynamic predictions of physical properties - prediction of solid solutions in molecular solutes exhibiting polymorphism. Chem Eng Techn 29:182-186.
43. Weissbuch I, Addadi L, Lahav M, Leiserowitz L. 1991. Molecular recognition at crystal interfaces. Science 253:637-645.
44. Mohan R, Koo KK, Strege C, Myerson AS. 2001. Effect of additives on the transformation behavior of L-phenylalanine in aqueous solution. Ind Eng Chem Res 40:6111-6117.
45. Davey RJ, Blagden N, Potts GD, Docherty R. 1997. Polymorphism in molecular crystals: Stabilization of a metastable form by conformational mimicry. J Am Chem Soc 119:1767-1772.
46. Gu C-H, Chatterjee K, Young V Jr, Grant DJW. 2002. Stabilization of a metastable polymorph of sulfmerazine by structurally related additives. J Cryst Growth 235:471-181.
47. Blagden N, Davey RJ, Rowe R, Roberts R. 1998. Disappearing polymorphs and the role of reaction by-products: The case of sulphathiazole. Int J Pharm 172:169-177.
48. Borchardt TB. 2001. Influence of Inpurities on the Crystallisation of Polymorphs of Eplerenone. 3rd International Symposium Crystallisation and Polymorphism Issues. Conference Proceeding, San Francisco, USA.
49. Bauer J, Spanton S, Henry R, Quick J, Dziki W, Porter W, Morris J. 2001. Ritonavir: An extraordinary example of conformational polymorphism. Pharmaceut Res 18:859-866.
50. San Agustin T. 2005. Personal Communication.
51. Johnson WS, Gravesto MB, Mccarry BE. 1971. Acetylenic bond participation in biogenetic-like olefinic cyclizations.2. Synthesis of Dl-progesterone. J Am Chem Soc 93:4332-4334.
52. Gravestock MB, Johnson WS, Mccarry BE, Parry RJ, Ratcliffe BE. 1978. Acetylenic bond participation in biomimetic polyene cyclizations - model studies directed toward synthesis of 20-keto steroids - synthesis of Dl-progesterone and Dl-delta-4-androstene-3,17-dione. J Am Chem Soc 100:4274-4282.
53. Johnson WS, Keana JFW, Johnson WS. 1963. Racemic Progesterone. Tetrahedron Lett 193-196.
54. Keana JFW. 1965. The total synthesis of progesterone, cholesterol, and closely related natural products. Thesis/Dissertation.
55. Gravestock MB, 2005. Characterisation of dl-progesterone. Personal Communication.
56. Gravestock MB, 2005. Total synthesis of racemic progesterone. Personal Communication.
57. Biellmann JF. 2003. Enantiomeric steroids: Synthesis, physical, and biological properties. Chem Rev 103:2019-2033.
58. Ostwald WZ. 1897. Studies on the formation and transformation of solid phases. Z Phys Chem 22: 289.
59. Threlfall T. 2003. Structural and thermodynamic explanations of Ostwald's rule. Organic Process Res Dev 7:1017-1027.
60. Bernstein J, Davey RJ, Henck JO. 1999. Concomitant polymorphs. Angew Chem, Int Ed 38:3441-3461.
61. Byrn S, Pfeiffer R, Ganey M, Hoiberg C, Poochikian G. 1995. Pharmaceutical solids - a strategic approach to regulatory considerations. Pharmaceut Res 12:945-954.